On August 20, 2025, Calidi Biotherapeutics, Inc. announced they entered an underwriting agreement to sell 1,922,764 common stock units and 1,528,000 pre-funded warrant units, raising approximately $6.9 million for working capital and clinical studies. The offering closed on August 21, 2025.